Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors

References

• Morton LM, Wang SS, Devesa SS, . Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, . Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Bertino JR, Glassman JR, . Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3776–3785.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, . Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684–3688.
   PubMed Web of Science ®Google Scholar
• Philip T, Armitage JO, Spitzer G, . High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493–1498.
   PubMed Web of Science ®Google Scholar
• Ashraf U, Mahajan R, Hahn T, . The effects of rituximab added to front-line or salvage chemotherapy in diffuse large B-cell lymphoma (DLBCL) undergoing high-dose chemotherapy (HDC) and autologous stem cell transplant (ASCT). Blood 2008;112(Suppl. 1): Abstract 1138.
   Google Scholar
• Martin A, Conde E, Arnan M, . R-ESHAP as salvage therapy for patients with re0lapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008;93:1829–1836.
   PubMed Web of Science ®Google Scholar
• Gutierrez M, Chabner BA, Pearson D, . Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000;18:3633–3642.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Zelenetz AD, Kewalramani T, . Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102: 1989–1996.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Hedrick EE, . High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000;96:2399–2404.
   PubMed Web of Science ®Google Scholar
• Prince HM, Imrie K, Crump M, . The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br J Haematol 1996;92: 880–889.
   PubMed Web of Science ®Google Scholar
• Martelli M, Vignetti M, Zinzani PL, . High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996;14:534–542.
   PubMed Web of Science ®Google Scholar
• Josting A, Reiser M, Rueffer U, . Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol 2000;18:332–339.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   PubMed Web of Science ®Google Scholar
• Mollee P, Pereira D, Nagy T, . Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant 2002;30:273–278.
   PubMed Web of Science ®Google Scholar
• Seshadri T, Al-Farsi K, Stakiw J, . G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation. Bone Marrow Transplant 2008;42:733–737.
   PubMed Web of Science ®Google Scholar
• Villela L, Lopez-Guillermo A, Montoto S, . Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer 2001;91:1557–1562.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, . Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117–122.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 1997;11:937–947.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Bergman AM, Ruiz van Haperen VW, . Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;22(Suppl. 11):72–79.
   PubMed Web of Science ®Google Scholar
• Vellenga E, van Putten WL, van't Veer MB, . Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 + NHL: a prospective randomized HOVON trial. Blood 2008;111:537–543.
   PubMed Web of Science ®Google Scholar
• Glass B, Borgerding A, Ziepert M, . Outcome of elderly patients with DLBCL failing R-CHOP: the role of rituximab and high dose therapy in second line treatment. A retrospective analysis from the RICOVER 60 trial. Blood 2009;114(Suppl. 1): Abstract 3714.
   Google Scholar
• Haioun C, Morschhauser F, Jourdan E, . Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2010;28(15 Suppl.): Abstract 8069.
   Google Scholar
• Crump M, Shepherd L, Lin B. A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive B-cell and T-cell non-Hodgkin's lymphoma. Clin Lymphoma 2005;6:56–60.
   PubMedGoogle Scholar
• Velasquez WS, McLaughlin P, Tucker S, . ESHAP–an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169–1176.
   PubMed Web of Science ®Google Scholar
• Chopra R, Linch DC, McMillan AK, . Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol 1992;81:197–202.
   PubMed Web of Science ®Google Scholar
• Mead GM, Sydes MR, Walewski J, . An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002;13:1264–1274.
   PubMed Web of Science ®Google Scholar